Lurbinectedin is a drug that has been studied for several years. According to DrugPatentWatch [1], the first patent for Lurbinectedin was filed in 2005, and the drug was first studied in clinical trials in 2008. The drug has been tested in various clinical trials, including Phase I, II, and III trials, to evaluate its safety and efficacy in treating various types of cancer, including ovarian, lung, and small cell lung cancer [2]. The clinical trials have been conducted in different countries, including the United States, Europe, and Asia [2]. In 2020, the U.S. Food and Drug Administration (FDA) approved Lurbinectedin for the treatment of metastatic small cell lung cancer [3].

In conclusion, Lurbinectedin has been studied for over a decade, with clinical trials conducted in various countries to evaluate its safety and efficacy in treating different types of cancer. The drug was first studied in clinical trials in 2008 and was approved by the FDA in 2020 for the treatment of metastatic small cell lung cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf